There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on IDEAYA Biosciences (IDYA – Research Report), Surgery Partners (SGRY – Research Report) and Beam Therapeutics (BEAM – Research Report) with bullish sentiments.
IDEAYA Biosciences (IDYA)
Citi analyst Yigal Nochomovitz maintained a Buy rating on IDEAYA Biosciences yesterday and set a price target of $60.00. The company’s shares closed last Tuesday at $42.75.
According to TipRanks.com, Nochomovitz is a 5-star analyst with an average return of
IDEAYA Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $53.75.
See today’s best-performing stocks on TipRanks >>
Surgery Partners (SGRY)
In a report released yesterday, Jason Cassorla from Citi maintained a Buy rating on Surgery Partners, with a price target of $38.00. The company’s shares closed last Tuesday at $27.77.
According to TipRanks.com, Cassorla ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Surgery Partners with a $43.10 average price target, which is a 56.7% upside from current levels. In a report issued on May 1, Benchmark Co. also reiterated a Buy rating on the stock with a $50.00 price target.
Beam Therapeutics (BEAM)
Citi analyst Samantha Semenkow maintained a Buy rating on Beam Therapeutics yesterday and set a price target of $56.00. The company’s shares closed last Tuesday at $22.53.
According to TipRanks.com, Semenkow is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Beam Therapeutics with a $47.56 average price target, a 109.0% upside from current levels. In a report released yesterday, William Blair also maintained a Buy rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on IDYA:
- IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
- Ideaya Biosciences announces selection of move-forward expansion dose for IDE397
- Ideaya Biosciences announces inducement grants under Nasdaq listing rule
- TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal
- Ideaya Biosciences participates in a conference call with JPMorgan
